Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2021-09-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030338423652352 |
|---|---|
| author | E. A. Rezukhina O. V. Rodnenkov T. V. Martynyuk |
| author_facet | E. A. Rezukhina O. V. Rodnenkov T. V. Martynyuk |
| author_sort | E. A. Rezukhina |
| collection | DOAJ |
| description | We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease in effort tolerance. According to a comprehensive examination, single factors of high risk and unfavorable prognosis were identified. Due to systemic hypotension when using inhaled iloprost, selexipag was added to therapy. According to control hospitalization, 8-month selexipag therapy improved the patient's condition, as well as high risk factors were not revealed. Selexipag is a selective oral prostacyclin receptor agonist recommended for longterm IPAH therapy in adult patients. |
| format | Article |
| id | doaj-art-867be1d2cb784d6b815586743556e2fc |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2021-09-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-867be1d2cb784d6b815586743556e2fc2025-08-20T02:59:14Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252021-09-0120510.15829/1728-8800-2021-30102317Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case reportE. A. Rezukhina0O. V. Rodnenkov1T. V. Martynyuk2National Medical Research Center of CardiologyNational Medical Research Centre of cardiology of Ministry of HealthNational Medical Research Center of Cardiology; Pirogov Russian National Research Medical UniversityWe present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease in effort tolerance. According to a comprehensive examination, single factors of high risk and unfavorable prognosis were identified. Due to systemic hypotension when using inhaled iloprost, selexipag was added to therapy. According to control hospitalization, 8-month selexipag therapy improved the patient's condition, as well as high risk factors were not revealed. Selexipag is a selective oral prostacyclin receptor agonist recommended for longterm IPAH therapy in adult patients.https://cardiovascular.elpub.ru/jour/article/view/3010pulmonary arterial hypertensionidiopathic pulmonary hypertensionprostacyclin receptor agonistselexipag |
| spellingShingle | E. A. Rezukhina O. V. Rodnenkov T. V. Martynyuk Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report Кардиоваскулярная терапия и профилактика pulmonary arterial hypertension idiopathic pulmonary hypertension prostacyclin receptor agonist selexipag |
| title | Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report |
| title_full | Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report |
| title_fullStr | Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report |
| title_full_unstemmed | Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report |
| title_short | Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report |
| title_sort | prostacyclin receptor agonist selexipag in a patient with high risk idiopathic pulmonary arterial hypertension a case report |
| topic | pulmonary arterial hypertension idiopathic pulmonary hypertension prostacyclin receptor agonist selexipag |
| url | https://cardiovascular.elpub.ru/jour/article/view/3010 |
| work_keys_str_mv | AT earezukhina prostacyclinreceptoragonistselexipaginapatientwithhighriskidiopathicpulmonaryarterialhypertensionacasereport AT ovrodnenkov prostacyclinreceptoragonistselexipaginapatientwithhighriskidiopathicpulmonaryarterialhypertensionacasereport AT tvmartynyuk prostacyclinreceptoragonistselexipaginapatientwithhighriskidiopathicpulmonaryarterialhypertensionacasereport |